The high trader consensus on "No" for a new COVID variant of concern before 2027 reflects sustained low risk from current SARS-CoV-2 evolution. As of mid-2026, neither WHO nor ECDC lists any variants meeting VOC criteria, with circulation limited to Omicron sublineages such as XFG and BA.3.2 under monitoring or interest status. BA.3.2 shows notable spike mutations and some immune escape signals but remains at low overall prevalence without driving increased severity or healthcare strain. Updated 2026-2027 vaccines target dominant strains like XFG, while multimodal surveillance including wastewater tracking shows no rapid shifts warranting escalation. This steady landscape, absent major changes in transmissibility or virulence, underpins the market's strong lean against a new designation in the short timeframe ahead.